NCT05713110 2025-01-22A Study of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory LymphomaHutchmedPhase 2 Completed61 enrolled
NCT02220842 2020-01-27A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell LymphomaHoffmann-La RochePhase 1 Completed96 enrolled